このエントリーをはてなブックマークに追加
ID 32200
JaLCDOI
フルテキストURL
著者
Ohnoshi, Taisuke Okayama University
Hiraki, Shunkichi Okayama Red Cross Hospital
Ueda, Nobuo Prefectural Medical Center of Ehime
Fujii, Masafumi National Shikoku Cancer Center
Machida, Ken-ichi Prefectural Medecal Center of Kochi
Ueoka, Hiroshi Okayama University
Kawahara, Shin Okayama University
Kozuka, Akira Okayama University
Kiura, Katsuyuki Okayama University ORCID Kaken ID publons researchmap
Moritaka, Tomonori Okayama University
Kodani, Tsuyoshi Okayama University
Kamei, Haruhito Okayama University
Kimura, Ikuro Okayama University
抄録

Twenty-seven previously untreated patients with unresectable non-small cell lung cancer were treated with a 3-drug combination of ifosfamide, cisplatin, and vindesine as a phase II study. Patients received ifosfamide, 1.3g/m2, on days 1 to 5; cisplatin, 20mg/m2, on days 1 to 5; and vindesine, 3mg/m2, on days 1 and 8; with a sufficient parenteral hydration. Courses were repeated every 4 weeks. Twenty males and seven females with a median age of 61 years were treated and fully evaluated. Five patients had stage IIIA, seven had stage IIIB, and 15 had stage IV disease. One patient with adenocarcinoma achieved a complete response and 16 achieved a partial response, for an overall response rate of 63% (95% confidence limit: 45% to 81%). The median duration of response was 34 weeks (range: 9 to 52 weeks). The median survival time was 58 weeks for patients with IIIA/B disease, and 33 weeks for those with IV disease. The major toxicity was myelosuppression, however, it was generally well-tolerated. These results indicate that the 3-drug combination is active against non-small cell lung cancer and warrants further clinical trials.

キーワード
non-small cell lung cancer
ifosfamide
cisplatin
vindesine
Amo Type
Article
発行日
1991-10
出版物タイトル
Acta Medica Okayama
45巻
5号
出版者
Okayama University Medical School
開始ページ
357
終了ページ
361
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT